سعر افيروميلان 50مجم 30 قرص 2026

Milnacipran 50 mg film-coated tablets, 30 tablets; serotonin-norepinephrine reuptake inhibitor classed as an antidepressant in Egypt (Averroes Pharma, Egypt).

• Management of fibromyalgiaPopulation: Adults (not approved for pediatric patients)DailyMed (U.S. National Library of Medicine)

• Most frequent adverse reaction in fibromyalgia trials: nausea. Most common (≥5% and twice placebo): constipation, hot flush, hyperhidrosis, vomiting, palpitations, increased heart rate, dry mouth and hypertension.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Use with MAOIs intended to treat psychiatric disorders or within 5 days of stopping milnacipran; use within 14 days of stopping such an MAOI; starting in patients treated with linezolid or intravenous methylene blue (serotonin syndrome risk).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - suicidality and antidepressant drugs: antidepressants increased suicidal thinking and behavior in children, adolescents and young adults; monitor for clinical worsening, suicidality and unusual behavior changes.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serotonin syndrome, especially with other serotonergic drugs (triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, St John's Wort) or drugs impairing serotonin metabolism.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Increases blood pressure and heart rate: measure before starting and periodically; treat pre-existing hypertension and cardiac disease before starting; consider dose reduction or discontinuation if sustained increases occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Monoamine oxidase inhibitors (including linezolid and intravenous methylene blue)Contraindicated combination (serotonin syndrome); observe the 14-day/5-day washout intervals.DailyMed (U.S. National Library of Medicine)
• Serotonergic drugs (triptans, SSRIs/SNRIs, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, St John's Wort)Risk of serotonin syndrome; monitor, especially at treatment start and dose increases.DailyMed (U.S. National Library of Medicine)
• Epinephrine and norepinephrineMilnacipran inhibits norepinephrine reuptake and may be associated with paroxysmal hypertension and possible arrhythmia with these catecholamines.DailyMed (U.S. National Library of Medicine)

• Data in pregnant women are insufficient to evaluate risk of birth defects or miscarriage; SNRI exposure in the month before delivery is associated with a less than 2-fold increase in postpartum hemorrhage risk; neonates exposed late in the third trimester may develop complications needing prolonged hospitalization.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Milnacipran is present in human milk; no reports on effects in breastfed infants, but agitation, irritability, poor feeding and poor weight gain have been reported with SSRIs/SNRIs. Monitor the infant for sedation, agitation, irritability, poor feeding and poor weight gain.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Milnacipran hydrochloride: Potent inhibitor of neuronal norepinephrine and serotonin reuptake (about 3-fold more potent for norepinephrine in vitro) without direct effect on dopamine uptake; mechanism in fibromyalgia unknown (US label).